" class="no-js "lang="en-US"> SpliceBio - Medtech Alert
Tuesday, September 16, 2025
SpliceBio | Pharmtech Focus

SpliceBio

About SpliceBio

SpliceBio

SpliceBio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. www.splice.bio.

Related Story

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

February 16 2022

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced […]